At Highland Therapeutics we use proprietary drug-delivery technology to develop improved versions of existing drug products.
President & Chief Executive Officer
David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Highland Therapeutics.
Under his leadership, Highland has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.
Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.
Chief Financial Officer
Nelson F. Isabel serves as the Company’s Chief Financial Officer.
Prior to joining Highland, Mr. Isabel spent seven years at Biovail Corporation (now Valeant Pharmaceuticals International, Inc.), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.
Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.
Executive Vice President,
Commercial Strategy and Operations
Thomas A. Curatolo serves as the Company’s Executive Vice President, Commercial Strategy and Operations.
Prior to joining the Company, Mr. Curatolo spent nine years at Shire Pharmaceuticals. Most recently, he served in the capacity of Vice President, Global Commercial Operations and Commercial Strategy Lead for the Neuroscience Business Unit, which generated $2.2 billion in revenues in 2014. Throughout his career, Mr. Curatolo has been focused on the ADHD market, leading pre-launch, launch and mature product marketing teams for methylphenidate and amphetamine formulations, as well as non-stimulant products, covering the entire spectrum of current ADHD pharmacologic treatment.
Mr. Curatolo has a B.A. in Environmental Economics from Rutgers University and a Master of Business Administration in Marketing Management from St. John’s University.
Highland Therapeutics Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary drugs utilizing a proprietary drug delivery system named DELEXIS®.
Highland’s lead compounds, HLD-100 (amphetamine) and HLD-200 (methylphenidate) are under development for the treatment of symptoms associated with Attention-Deficit/Hyperactivity Disorder, or ADHD.
Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine.
A majority of surveyed families report ADHD symptoms as ‘severe’ or ‘moderate-to-severe’ during the morning routine – the period immediately upon waking until the patient leaves for work or school. This period is often the busiest and most chaotic for families.
Highland has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.